ErbB signaling (WP673)

Homo sapiens

Open in new tab Open in NDEx Open in Newt (SBGN)

Download PNG Download SVG Download JSON Download GPML Learn more about Downloads

Authors

Activity

Discuss this pathway

Check for ongoing discussions or start your own.

Cited In

• Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. Clinical outcome and actionable molecular alterations☆ (2021).
• The Application of the Open Pharmacological Concepts Triple Store (Open PHACTS) to Support Drug Discovery Research (2014).
• CyTargetLinker: A Cytoscape App to Integrate Regulatory Interactions in Network Analysis (2013).
• Novel kinome profiling technology reveals drug treatment is patient and 2D/3D model dependent in glioblastoma (2022).
• Shared mechanisms and crosstalk of COVID-19 and osteoporosis via vitamin D (2022).
• Gastric cancer actionable genomic alterations across diverse populations worldwide and pharmacogenomics strategies based on precision oncology (2024).
• MicroRNAs as potential biomarkers for doxorubicin-induced cardiotoxicity.
• A Practical Strategy for Exploring the Pharmacological Mechanism of Luteolin Against COVID-19/Asthma Comorbidity: Findings of System Pharmacology and Bioinformatics Analysis (2024).

Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.

Organisms

Communities

Annotations

Disease Ontology

Pathway Ontology

References

1. Phosphorylation of CrkII adaptor protein at tyrosine 221 by epidermal growth factor receptor. Hashimoto Y, Katayama H, Kiyokawa E, Ota S, Kurata T, Gotoh N, et al. J Biol Chem. 1998 Jul 3;273(27):17186–91. PubMed Europe PMC Scholia
2. The Nck SH2/SH3 adaptor protein: a regulator of multiple intracellular signal transduction events. McCarty JH. Bioessays. 1998 Nov;20(11):913–21. PubMed Europe PMC Scholia
3. Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers. Muthuswamy SK, Gilman M, Brugge JS. Mol Cell Biol. 1999 Oct;19(10):6845–57. PubMed Europe PMC Scholia
4. The ErbB signaling network: receptor heterodimerization in development and cancer. Olayioye MA, Neve RM, Lane HA, Hynes NE. EMBO J. 2000 Jul 3;19(13):3159–67. PubMed Europe PMC Scholia
5. Untangling the ErbB signalling network. Yarden Y, Sliwkowski MX. Nat Rev Mol Cell Biol. 2001 Feb;2(2):127–37. PubMed Europe PMC Scholia
6. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Liang J, Slingerland JM. Cell Cycle. 2003;2(4):339–45. PubMed Europe PMC Scholia
7. ErbB receptors: directing key signaling networks throughout life. Holbro T, Hynes NE. Annu Rev Pharmacol Toxicol. 2004;44:195–217. PubMed Europe PMC Scholia
8. Signal transduction and oncogenesis by ErbB/HER receptors. Marmor MD, Skaria KB, Yarden Y. Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):903–13. PubMed Europe PMC Scholia
9. ERBB4/HER4 potentiates STAT5A transcriptional activity by regulating novel STAT5A serine phosphorylation events. Clark DE, Williams CC, Duplessis TT, Moring KL, Notwick AR, Long W, et al. J Biol Chem. 2005 Jun 24;280(25):24175–80. PubMed Europe PMC Scholia
10. ERBB receptors and cancer: the complexity of targeted inhibitors. Hynes NE, Lane HA. Nat Rev Cancer. 2005 May;5(5):341–54. PubMed Europe PMC Scholia
11. Epidermal growth factor receptor (EGFR) signaling in cancer. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, et al. Gene. 2006 Jan 17;366(1):2–16. PubMed Europe PMC Scholia
12. Phosphotyrosine interactome of the ErbB-receptor kinase family. Schulze WX, Deng L, Mann M. Mol Syst Biol. 2005;1:2005.0008. PubMed Europe PMC Scholia
13. A comprehensive pathway map of epidermal growth factor receptor signaling. Oda K, Matsuoka Y, Funahashi A, Kitano H. Mol Syst Biol. 2005;1:2005.0010. PubMed Europe PMC Scholia
14. EGF-ERBB signalling: towards the systems level. Citri A, Yarden Y. Nat Rev Mol Cell Biol. 2006 Jul;7(7):505–16. PubMed Europe PMC Scholia
15. The epidermal growth factor receptor pathway: a model for targeted therapy. Scaltriti M, Baselga J. Clin Cancer Res. 2006 Sep 15;12(18):5268–72. PubMed Europe PMC Scholia
16. Up-regulation of miR-21 by HER2/neu signaling promotes cell invasion. Huang TH, Wu F, Loeb GB, Hsu R, Heidersbach A, Brincat A, et al. J Biol Chem. 2009 Jul 3;284(27):18515–24. PubMed Europe PMC Scholia
17. Case records of the Massachusetts General Hospital. Case 19-2010. A 35-year-old man with adenocarcinoma of the cecum. Ryan DP, Engelman JA, Ferrone CR, Sahani DV, Lisovsky M. N Engl J Med. 2010 Jun 24;362(25):2411–9. PubMed Europe PMC Scholia
18. PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Hornbeck PV, Zhang B, Murray B, Kornhauser JM, Latham V, Skrzypek E. Nucleic Acids Res. 2015 Jan;43(Database issue):D512-20. PubMed Europe PMC Scholia